Zoledronic Acid Alters Hematopoiesis and Generates Breast Tumor-suppressive Bone Marrow Cells

Overview

Journal Breast Cancer Res

Specialty Oncology

Date 2017 Mar 8

PMID 28264701

Citations 21

Authors

Jessalyn M Ubellacker

Marie-Therese Haider

Molly J DeCristo

Gloria Allocca

Nicola J Brown

Daniel P Silver

Ingunn Holen

Sandra S McAllister

Affiliations

Soon will be listed here.

Abstract

Background: The bone-targeting agent zoledronic acid (ZOL) increases breast cancer survival in subsets of patients, but the underlying reasons for this protective effect are unknown. ZOL modulates the activity of osteoclasts and osteoblasts, which form hematopoietic stem cell niches, and therefore may affect hematopoietic cells that play a role in breast cancer progression.

Method: Immunocompetent and immunocompromised strains of mice commonly used for breast cancer research were injected with a single, clinically relevant dose of ZOL (100 μg/kg) or vehicle control. The effects of ZOL on the bone marrow microenvironment (bone volume, bone cell number/activity, extracellular matrix composition) were established at various time points following treatment, using micro-computed tomography (μCT) analysis, histomorphometry, ELISA and immunofluorescence. The effects on peripheral blood and bone marrow hematopoietic progenitor populations were assessed using a HEMAVET® hematology analyzer and multicolor flow cytometry, respectively. Tumor support function of bone marrow cells was determined using an in vivo functional assay developed in our laboratory.

Results: Using multiple mouse strains, we observed transient changes in numbers of hematopoietic stem cells, myeloid-biased progenitor cells, and lymphoid-biased cells concurrent with changes to hematopoietic stem cell niches following ZOL administration. Importantly, bone marrow cells from mice treated with a single, clinically relevant dose of ZOL inhibited breast tumor outgrowth in vivo. The ZOL-induced tumor suppressive function of the bone marrow persisted beyond the time point at which numbers of hematopoietic progenitor cells had returned to baseline.

Conclusions: These findings provide novel evidence that alterations to the bone marrow play a role in the anti-tumor activity of ZOL and suggest possibilities for capitalizing on the beneficial effects of ZOL in reducing breast cancer development and progression.

Citing Articles

A Pragmatic Approach to Introducing Translational Geroscience Into the Clinic: A Paradigm Based on the Incremental Progression of Aging-Related Clinical Research.

Forman D, Pignolo R J Gerontol A Biol Sci Med Sci. 2024; 79(9).

PMID: 39126296 PMC: 11316203. DOI: 10.1093/gerona/glae062.

Quantitative Analysis of Bone, Blood Vessels, and Metastases in Mice Tibiae Using Synchrotron Radiation Micro-Computed Tomography.

Xu H, Langer M Cancers (Basel). 2023; 15(23).

PMID: 38067313 PMC: 10705077. DOI: 10.3390/cancers15235609.

Indication and adverse event profiles of denosumab and zoledronic acid: based on U.S. FDA adverse event reporting system (FAERS).

Su S, Wu L, Zhou G, Peng L, Zhao H, Wang X Front Pharmacol. 2023; 14:1225919.

PMID: 38027014 PMC: 10654638. DOI: 10.3389/fphar.2023.1225919.

Systemic administration of STING agonist promotes myeloid cells maturation and antitumor immunity through regulating hematopoietic stem and progenitor cell fate.

Xu T, Dai J, Tang L, Sun L, Si L, Guo J Cancer Immunol Immunother. 2023; 72(11):3491-3505.

PMID: 37550427 PMC: 10991199. DOI: 10.1007/s00262-023-03502-7.

and effects of zoledronic acid on senescence and senescence-associated secretory phenotype markers.

Samakkarnthai P, Saul D, Zhang L, Aversa Z, Doolittle M, Sfeir J Aging (Albany NY). 2023; 15(9):3331-3355.

PMID: 37154858 PMC: 10449299. DOI: 10.18632/aging.204701.

References

Calvi L, Adams G, Weibrecht K, Weber J, Olson D, Knight M . Osteoblastic cells regulate the haematopoietic stem cell niche. Nature. 2003; 425(6960):841-6. DOI: 10.1038/nature02040. View

McAllister S, Gifford A, Greiner A, Kelleher S, Saelzler M, Ince T . Systemic endocrine instigation of indolent tumor growth requires osteopontin. Cell. 2008; 133(6):994-1005. PMC: 4121664. DOI: 10.1016/j.cell.2008.04.045. View

Ottewell P, Woodward J, Lefley D, Evans C, Coleman R, Holen I . Anticancer mechanisms of doxorubicin and zoledronic acid in breast cancer tumor growth in bone. Mol Cancer Ther. 2009; 8(10):2821-32. DOI: 10.1158/1535-7163.MCT-09-0462. View

Mendez-Ferrer S, Michurina T, Ferraro F, Mazloom A, MacArthur B, Lira S . Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature. 2010; 466(7308):829-34. PMC: 3146551. DOI: 10.1038/nature09262. View

Cho K, Joo S, Han H, Ryu K, Woo S . Osteoclast activation by receptor activator of NF-kappaB ligand enhances the mobilization of hematopoietic progenitor cells from the bone marrow in acute injury. Int J Mol Med. 2010; 26(4):557-63. DOI: 10.3892/ijmm_00000499. View

Orkin S, Zon L . Hematopoiesis: an evolving paradigm for stem cell biology. Cell. 2008; 132(4):631-44. PMC: 2628169. DOI: 10.1016/j.cell.2008.01.025. View

Young R, Coleman R . Zoledronic acid to prevent and treat cancer metastasis: new prospects for an old drug. Future Oncol. 2013; 9(5):633-43. DOI: 10.2217/fon.13.28. View

Gao D, Mittal V . The role of bone-marrow-derived cells in tumor growth, metastasis initiation and progression. Trends Mol Med. 2009; 15(8):333-43. DOI: 10.1016/j.molmed.2009.06.006. View

Ottewell P, Wang N, Brown H, Reeves K, Fowles C, Croucher P . Zoledronic acid has differential antitumor activity in the pre- and postmenopausal bone microenvironment in vivo. Clin Cancer Res. 2014; 20(11):2922-32. PMC: 4040234. DOI: 10.1158/1078-0432.CCR-13-1246. View

10.

Kollet O, Dar A, Shivtiel S, Kalinkovich A, Lapid K, Sztainberg Y . Osteoclasts degrade endosteal components and promote mobilization of hematopoietic progenitor cells. Nat Med. 2006; 12(6):657-64. DOI: 10.1038/nm1417. View

11.

McAllister S, Weinberg R . The tumour-induced systemic environment as a critical regulator of cancer progression and metastasis. Nat Cell Biol. 2014; 16(8):717-27. PMC: 6220424. DOI: 10.1038/ncb3015. View

12.

Rodan G . Mechanisms of action of bisphosphonates. Annu Rev Pharmacol Toxicol. 1998; 38:375-88. DOI: 10.1146/annurev.pharmtox.38.1.375. View

13.

Coscia M, Quaglino E, Iezzi M, Curcio C, Pantaleoni F, Riganti C . Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway. J Cell Mol Med. 2009; 14(12):2803-15. PMC: 3822730. DOI: 10.1111/j.1582-4934.2009.00926.x. View

14.

Kiel M, Yilmaz O, Iwashita T, Yilmaz O, Terhorst C, Morrison S . SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. Cell. 2005; 121(7):1109-21. DOI: 10.1016/j.cell.2005.05.026. View

15.

Allegra A, Oteri G, Nastro E, Alonci A, Bellomo G, Del Fabro V . Patients with bisphosphonates-associated osteonecrosis of the jaw have reduced circulating endothelial cells. Hematol Oncol. 2007; 25(4):164-9. DOI: 10.1002/hon.819. View

16.

Jain N, Weinstein R . Giant osteoclasts after long-term bisphosphonate therapy: diagnostic challenges. Nat Rev Rheumatol. 2009; 5(6):341-6. PMC: 2860596. DOI: 10.1038/nrrheum.2009.87. View

17.

Viereck V, Emons G, Lauck V, Frosch K, Blaschke S, Grundker C . Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts. Biochem Biophys Res Commun. 2002; 291(3):680-6. DOI: 10.1006/bbrc.2002.6510. View

18.

Morrison S, Scadden D . The bone marrow niche for haematopoietic stem cells. Nature. 2014; 505(7483):327-34. PMC: 4514480. DOI: 10.1038/nature12984. View

19.

Rogers M, Chilton K, Coxon F, Lawry J, Smith M, Suri S . Bisphosphonates induce apoptosis in mouse macrophage-like cells in vitro by a nitric oxide-independent mechanism. J Bone Miner Res. 1996; 11(10):1482-91. DOI: 10.1002/jbmr.5650111015. View

20.

Zhang J, Niu C, Ye L, Huang H, He X, Tong W . Identification of the haematopoietic stem cell niche and control of the niche size. Nature. 2003; 425(6960):836-41. DOI: 10.1038/nature02041. View